Balancing Innovation and Responsibility in Peptide Manufacturing

The pharmaceutical and biotechnology industries are embedding sustainability into drug discovery, with the peptide sector embracing green peptide chemistry to minimize environmental impact and improve efficiency.

Life Sciences Review | Thursday, March 26, 2026

The global pharmaceutical and biotechnology sectors are advancing beyond basic regulatory compliance, embedding sustainability into every stage of drug discovery and manufacturing. Within this shift, the research peptide industry has emerged as a leader in innovation. Once defined by chemically intensive methods and high solvent usage, the field is now rapidly adopting green peptide chemistry. This transformation represents more than an operational change, it reflects a strategic alignment with global sustainability priorities, reshaping how bioactive peptides are synthesized, purified and delivered.

Conventionally, peptide synthesis—particularly Solid-Phase Peptide Synthesis (SPPS)—relied heavily on hazardous polar aprotic solvents such as N, N-dimethylformamide (DMF), dichloromethane (DCM), and N-methyl-2-pyrrolidone (NMP). These substances, while effective, pose significant environmental and health risks and contribute to a large carbon footprint due to the high volumes required for washing and deprotection steps.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Manufacturers are increasingly adopting binary solvent systems, such as anisole combined with lesser amounts of greener polar components, or utilizing 2-methyltetrahydrofuran (2-MeTHF), a bio-derived solvent sourced from renewable agricultural byproducts. The industry is seeing a surge in the use of cyclopentyl methyl ether (CPME) and water-based surfactant technologies that enable lipophilic reactions in aqueous media.

Parallel to solvent replacement is the innovation in coupling reagents. Modern workflows prioritize reagents with high atom economy—maximizing the number of atoms from reactants that end up in the final product—thereby reducing byproduct formation. This "prevention at the source" approach is a cornerstone of green chemistry, ensuring that sustainability is designed into the synthesis protocol rather than managed as an afterthought.

Process Intensification and Energy Efficiency

Beyond chemical substitution, the physical methodology of peptide production has undergone a revolution aimed at drastic energy reduction. Traditional batch manufacturing is energy-intensive, often requiring prolonged heating and cooling cycles. The industry’s response has been the widespread adoption of flow chemistry and continuous manufacturing principles.

In flow chemistry, reactions occur in a continuously flowing stream rather than in static batches. This method significantly enhances heat and mass transfer, allowing reactions to proceed faster and with higher yields. The precise control offered by flow systems reduces thermal energy requirements and minimizes the need for excess reagents. Consequently, the manufacturing footprint shrinks, both physically and environmentally.

Another major stride is the optimization of downstream processing. Lyophilization (freeze-drying) has long been the industry standard for peptide isolation, yet it is energy-inefficient. Current trends indicate a shift toward alternative isolation techniques, such as spray drying and precipitation-crystallization. These methods not only consume a fraction of the energy but also allow for better control over particle engineering, which is crucial for the bioavailability of the final research product.

The Circular Economy in Peptide Synthesis

Waste management in peptide manufacturing is evolving from a linear "dispose" model to a circular "recover and repurpose" framework. Given that solvents can account for up to 90 per cent of the mass in peptide synthesis, their recovery is a high-priority sustainability target. Advanced distillation and membrane filtration technologies are now integral to modern facilities, enabling on-site solvent recycling with purity levels sufficient for re-use in subsequent wash cycles.

The industry is rethinking the solid supports used in SPPS. The development of biodegradable resins and the implementation of "atom-efficient" linkers ensure that the solid waste generated is less persistent in the environment. Innovations in membrane-enhanced peptide synthesis (MEPS) enable the separation of unreacted reagents from the growing peptide chain, allowing the recycling of valuable amino acids and coupling agents that would otherwise be discarded. This circular approach significantly reduces the E-factor (environmental factor) of production, a metric that measures the ratio of waste to product.

Ethical Supply Chains and Logistics

Sustainability extends beyond the laboratory walls to the global supply chain. Manufacturers are increasingly scrutinizing their upstream partners, prioritizing raw material suppliers who adhere to ethical labor practices and environmental stewardship. This includes sourcing amino acids produced via fermentation from renewable feedstocks rather than petrochemical routes.

Logistically, the industry is embracing "green distribution." This involves optimizing cold-chain storage to reduce energy consumption during transport and utilizing packaging materials derived from recycled or compostable sources. There is also a strategic trend toward near-shoring manufacturing capabilities. By locating production facilities closer to key research hubs, companies are drastically reducing the scope three emissions associated with global freight, ensuring that the carbon cost of delivering a peptide is as low as possible.

The research peptide industry’s collective initiatives reflect a strong and intentional alignment with the United Nations Sustainable Development Goals (SDGs). By advancing more efficient, cost-effective peptide synthesis, the sector supports SDG 3: Good Health and Well-being, enabling faster progress in developing therapeutics for metabolic disorders, oncology, and antimicrobial resistance. Its embrace of flow chemistry, automation, and digital technologies reinforces SDG 9: Industry, Innovation, and Infrastructure, driving modernization and enhancing industrial resilience. In parallel, the industry’s commitment to solvent recycling, green chemistry alternatives, and circular waste practices directly advances SDG 12: Responsible Consumption and Production, promoting safer chemical management and meaningful waste reduction. Additionally, ongoing efforts to lower energy use in manufacturing and to reduce carbon-intensive logistics support SDG 13: Climate Action, contributing to broader global initiatives to mitigate climate change.

No longer content with reactive compliance, the sector is embedding sustainability into the DNA of its operations. Through the convergence of green chemistry, process intensification, and circular economic models, manufacturers are proving that high-quality scientific output and environmental stewardship are not mutually exclusive—they are synergistic. As these technologies mature and scale, the industry is poised to serve as a global benchmark for sustainable pharmaceutical science, driving progress toward a healthier planet and a healthier population.

More in News

BIOSPAIN 2026 to Make Bilbao a European Hub for the Future of Biotechnology

• Spain’s leading biotechnology event will bring together companies, researchers, investors and institutions from more than 30 countries from 29 September to 1 October. • Advanced therapies, artificial intelligence, bioeconomy, European competitiveness and investment will be among the key topics shaping the programme. BIOSPAIN 2026 , Spain’s leading biotechnology event and one of Europe’s major international biotech gatherings, will take place from 29 September to 1 October at the Bilbao Exhibition Centre (BEC) under the theme “Bioinnovation that clicks” . Organised by the Spanish Bioindustry Association (AseBio), in collaboration with the Provincial Council of Bizkaia, the Basque Government and the Basque Health Cluster (BHC), the event will bring together key players from across the international biotechnology ecosystem. The scientific programme is structured around four main tracks – Policy , Health , Bioeconomy and Finance – addressing some of the issues set to shape biotechnology over the coming decade. International experts will discuss European competitiveness and strategic autonomy, advanced therapies and precision medicine, the impact of artificial intelligence on biomedical research, biotechnology-based solutions for a more sustainable economy, and the financing and technology transfer models needed to turn scientific excellence into globally competitive companies. Beyond the conference programme, BIOSPAIN will provide an international platform for business development, investment and collaboration . Companies, research centres, investors and institutions will be able to showcase their capabilities, identify potential partners and explore new business opportunities. In 2025, BIOSPAIN welcomed more than 2,400 attendees from 35 countries, brought together 140 investors from 76 national and international organisations, and facilitated more than 4,500 one-to-one business meetings. BIOSPAIN 2026 will return to the Basque Country for the third time, ten years after its previous edition in the region. The Basque Country has developed one of Southern Europe’s leading life sciences and health ecosystems, with more than 300 companies alongside research centres, universities, hospitals and scientific and technological infrastructures. The international dimension of this year’s edition will be further strengthened by the United Kingdom as Guest Nation , fostering new scientific, business and investment links between the British and Spanish biotechnology ecosystems. On 1 October, BIOSPAIN will also host its Talent Day , connecting biotechnology companies with researchers, PhD candidates, graduates and experienced professionals through job opportunities and pre-arranged interviews. With less than a month to go, BIOSPAIN 2026 will position Bilbao as a meeting point for the international biotech community to build partnerships, exchange knowledge and explore the innovations that will shape the future of the sector. ...Read more

Boosting Laboratory Accuracy: How Proficiency Testing Shapes the Future of Life Sciences

Life science proficiency testing service providers have emerged as indispensable components in the quality control process for all research laboratories, diagnostic laboratories, pharmaceutical companies, biotech firms, and regulatory bodies. Given that scientific activity has been increasing in complexity, there is a need for laboratories to have reliable mechanisms for measuring their analytical performance and validating test accuracy. The process of proficiency testing involves conducting independent evaluations through comparison to standards and other laboratories. Organizations that make use of proficiency testing services are showing their dedication towards quality management, constant improvement, and dependable scientific results, leading to increased confidence among stakeholders, partners, regulatory bodies, and clients in the highly competitive life science industry. Strengthening Laboratory Quality through Independent Performance Evaluation The first and foremost purpose of life science proficiency testing is to determine the performance of a laboratory based on standard test materials. This process enables laboratories to assess the analytical performance against the expected values while determining the areas that need improvement. Proficiency testing is not just limited to compliance but is an effective management tool that aids decision-making within laboratories. Consistent participation allows the laboratory to evaluate its test accuracy and identify trends before they affect the lab’s operations. Regular evaluation is useful in confirming the efficiency of testing techniques, instrument performance, personnel competence, and internal quality controls. Through the early identification of performance trends, necessary corrective measures can be taken to ensure the reliability of the lab operations. A third major benefit relates to the ability to meet accreditation requirements. Many laboratories work under tightly controlled conditions, where it is important to prove technical proficiency. Proficiency testing helps provide proof that the analysis process produces reliable results. This information is useful not only for external evaluations but also for building trust in clients and collaborators. As lab technology advances, there is an expansion of the proficiency testing program to cater to the development of new test methods, testing systems, and scientific fields. Providers of service keep on developing testing methods that correspond to the advancement of laboratories so that those participating can be able to assess their performances with methods that correspond to the current technological advancements. Supporting Operational Efficiency and Continuous Improvement Proficiency testing in the life sciences not only helps with quality assurance but is a tool for improving efficiency through the practice of monitoring performance and refining processes. Those laboratories that analyze their proficiency test results have the opportunity to assess the effectiveness of their procedures, their resource usage, and how consistent the process is. Professional development of employees is also enhanced through proficiency testing participation in a formalized manner. The professionals in laboratories get objective information on their performance in terms of their technical skills, which in turn helps in training programs aimed at enhancing analytical skills. This promotes continuous learning among employees as well as standardization of the tests in laboratories. Information about equipment maintenance, method validation and other operational processes is also derived from data gathered via proficiency testing. The trend of performance can be used to identify areas where improvements in the calibration process, quality information, and standard operating procedures can be made. Such initiatives will help to minimize variations and improve performance. Communication by the testing agencies and the laboratories that participate is even more useful for the success of the program. The information and training that laboratories can get from performance reports, technical assistance, and educational materials will assist in understanding the results of the evaluation and making improvements. Advancements in technology, in terms of the use of digitized techniques, have made proficiency testing easier and more convenient. Digitized reporting systems, data analysis software, and information management systems have helped make the process easy for participants and minimize the amount of work for administrators. Technology has enabled laboratories to concentrate more on scientific work. Building Long-Term Business Value through Reliable Scientific Performance High-quality laboratory work adds tangible business value in the life sciences industry through such activities as product development, submission to regulatory authorities, research partnerships, and business decision-making. Those businesses that consistently provide analytically accurate data enhance their professional standing, as well as build confidence in their customer base and regulatory partners. Proficiency testing is thus more than a quality process; it is a strategic business move. As collaboration in science on a global scale increases, there is a greater tendency for laboratories to engage in multicenter studies, international research projects, and also regulatory activities involving cross-border collaboration. Proficiency testing through standardization enables the creation of a level of consistency in analytical results within the laboratory, thus promoting collaborative science efforts. Future trends in the domain of life science proficiency testing services are expected to center around increased automation, data analysis capabilities, a wider range of testing options, and increased digitalization. Service providers that continue to innovate while preserving their scientific integrity will continue to be an asset to laboratories in search of reliable quality assurance solutions. Through the application of technical knowledge, continuous improvement, and excellent client service, the proficiency testing services help to enhance laboratory performance and efficiency as well as scientific integrity. ...Read more

Clinical Laboratories Become a Strategic Driver of Modern Healthcare

Clinical laboratories have always played an essential role in healthcare, but their influence now reaches far beyond test results. Every diagnosis, treatment plan and disease monitoring strategy depends on reliable laboratory data. What was once viewed primarily as a support function has become a critical contributor to clinical decision-making across the healthcare system. That shift is changing how healthcare organizations invest in laboratory capabilities. Hospitals, health systems and independent laboratories face growing demand for faster turnaround times, greater testing capacity and increasingly complex diagnostic services. Rising rates of chronic disease, an aging population and advances in precision medicine continue to increase the volume and sophistication of laboratory testing. The market reflects that momentum. Industry estimates place the global clinical laboratory services market at well over USD 250 billion, with steady growth expected throughout the coming decade. Demand continues to rise as healthcare providers rely more heavily on laboratory data to guide diagnosis, monitor treatment and improve patient outcomes. “Precision medicine is creating new opportunities, but it also requires laboratories to develop specialized expertise and adopt more sophisticated technologies.” North America remains one of the largest markets for clinical laboratory services, supported by advanced healthcare infrastructure, strong investment in diagnostics and continued innovation across laboratory technologies. Technology Is Reshaping Laboratory Workflows The modern clinical laboratory looks very different from the one that existed a decade ago. Automation has become a central part of laboratory operations. Routine processes that once required significant manual effort are increasingly handled by automated analyzers and robotic systems, allowing laboratory professionals to process higher test volumes while improving consistency. Digital platforms are also changing how laboratories manage information. Laboratory information systems connect instruments, patient records and reporting workflows, giving clinicians faster access to results and reducing the risk of transcription errors. Molecular diagnostics continue to expand the laboratory’s role. Advances in genetic testing, biomarker analysis and next-generation sequencing are helping clinicians identify diseases earlier and select therapies that are better matched to individual patients. Precision medicine is creating new opportunities, but it also requires laboratories to develop specialized expertise and adopt more sophisticated technologies. Demand Continues to Grow Across Healthcare Several long-term trends continue to shape the clinical laboratory market. Chronic diseases such as diabetes, cardiovascular disease and cancer require regular monitoring, increasing the demand for laboratory testing throughout a patient’s care journey. Preventive healthcare is also becoming more common. Earlier diagnosis and routine screening programs are expanding testing volumes across primary care, specialty clinics and community health settings. Public health preparedness remains another important priority. Lessons learned during recent global health emergencies reinforced the need for laboratory networks that can rapidly scale testing capacity while maintaining quality and accuracy. Patients have become more engaged in their healthcare decisions as well. Many now expect quicker access to test results, greater transparency and more convenient testing options, encouraging laboratories to improve both efficiency and the patient experience. What Healthcare Organizations Expect From Laboratory Partners. Choosing a clinical laboratory is no longer based solely on testing capability. Healthcare organizations evaluate laboratories across a broader range of factors, including quality systems, regulatory compliance, turnaround times and the ability to support increasingly complex diagnostic requirements. Integration has become equally important. Laboratory systems are expected to connect smoothly with electronic health records and other healthcare platforms, allowing clinicians to access results quickly and incorporate laboratory data into broader care decisions. Scalability also plays an important role. Laboratories must be able to accommodate fluctuations in testing volumes without compromising quality or turnaround times. Workforce challenges continue to affect the sector. Many laboratories face shortages of experienced professionals while managing growing testing demand. Automation and digital technologies help address some of these pressures, yet skilled laboratory scientists remain essential for complex analysis, quality assurance and clinical interpretation. Standardization presents another ongoing challenge. Large health systems often operate multiple laboratories with different equipment, workflows and reporting practices. Greater consistency across laboratory networks can improve efficiency while supporting more reliable clinical outcomes. A Broader Role in the Future of Healthcare Clinical laboratories are becoming increasingly central to modern healthcare. Advances in diagnostics, precision medicine and digital health will continue to expand the laboratory’s contribution to patient care. At the same time, healthcare organizations will expect laboratories to deliver faster results, greater accuracy and stronger data integration while maintaining rigorous quality standards. Future investment is likely to focus on technologies that improve efficiency without sacrificing clinical confidence. Automation, molecular diagnostics and connected laboratory systems will continue to shape how testing services evolve over the coming years. Clinical laboratories are no longer viewed simply as places where samples are analyzed. They have become trusted partners in diagnosis, disease management and clinical decision-making, helping healthcare providers deliver more informed care in an increasingly complex healthcare environment. ...Read more

Hospital-Based Stem Cell Programs Highlight the Access Challenge

Stem cell treatment centers are becoming more important in regions where patients need complex transplant services but must travel far from home for care. While public attention often focuses on regenerative medicine clinics, established stem cell treatment is most mature in areas such as blood cancers and serious blood disorders, where transplant programs require specialized hospital infrastructure. A recent report from Australia described a campaign to establish a donor stem cell transplant service at Townsville University Hospital. The initiative aims to reduce the need for patients in North Queensland to travel to Brisbane for Total Body Irradiation before some stem cell transplants. This process can force patients and full-time carers to live away from home for months. Where stem cell treatment is available can have a significant impact on the patient experience. Treatment often involves much more than a single clinical procedure, including pre-treatment conditioning, donor coordination, infection monitoring and an extended period of recovery. When these services are concentrated in major cities, patients and their families may have to travel long distances, take extended time away from work or home and manage the financial and personal strain that comes with receiving care far from their local community. Treatment centers that expand access must still maintain high standards. A transplant program needs trained clinicians, laboratory support, inpatient capacity and emergency response systems. The complexity makes it different from office-based regenerative medicine offerings that may be marketed directly to consumers. Health systems are therefore looking at hub-and-spoke models. A major center may manage advanced procedures, while regional providers support testing, follow-up care and patient education. Expanding stem cell treatment services depends on people as much as infrastructure. A successful program requires experienced hematologists, transplant nurses, pharmacists and laboratory teams working together throughout the patient's care journey. Investing in equipment alone is not enough. Centers also need a coordinated model of care that can support patients before treatment, during therapy and throughout recovery. For patients considering stem cell treatment, it should be clear whether a service is part of an established hospital program or an unapproved commercial offering. That distinction has become increasingly important as stem cell therapies attract wider attention. The FDA continues to advise consumers to avoid unapproved products made from human cells or tissues that are marketed online with broad treatment claims. Stem cell treatment providers are increasingly following different paths. Hospital-based programs continue to build around approved therapies, multidisciplinary care and the clinical infrastructure needed to manage complex patients. At the same time, commercial clinics offering unapproved interventions are coming under closer regulatory and scientific scrutiny. As more treatment options emerge, centers that expand access without compromising clinical standards are likely to earn greater confidence from patients, physicians and regulators. ...Read more

Specials

Balancing Innovation and Responsibility in Peptide Manufacturing

The pharmaceutical and biotechnology industries are embedding sustainability into drug discovery, with the peptide sector embracing green peptide chemistry to minimize environmental impact and improve efficiency.